Abstract
Background Sodium glucose cotransporter 2 (SGLT2) inhibitors improve clinical outcomes in several populations including type 2 diabetes, chronic renal insufficiency, and heart failure (HF). However, limited data exist on their effects on atrial fibrillation (AF).
Methods We conducted a retrospective cohort study using the National Health Insurance Service database. A total of 4,771 patients with type 2 diabetes and AF who were newly prescribed SGLT2 inhibitors or DPP4 inhibitors were selected and matched in a 1:2 ratio by propensity score with 37 confounding variables. We assessed the effect of SGLT2 inhibitors on the composite outcome of either HF hospitalization or death compared with DPP4 inhibitors.
Results Over a median follow-up of 31 months, patients on SGLT2 inhibitors were associated with a lower risk of hospitalizations for HF or mortality compared to those on DPP4 inhibitors (HR 0.61; 95% CI 0.44-0.85; P=0.004). SGLT2 inhibitor use was also associated with a lower risk of mortality (HR 0.61; 95% CI 0.39-0.94; P=0.025) and CV mortality (HR 0.43; 95% CI 0.21-0.86; P=0.018), but not of MI (HR 1.22 [95% CI 0.72-2.09]; P=0.461) or stroke (HR 1.00 [95% CI 0.75-1.33]; P=0.980). The incidence of hospitalizations for HF, although statistically insignificant, tended to be lower in the SGLT2 inhibitor group (HR 0.63 [95% CI 0.39-1.02]; P=0.062).
Conclusion In a nationwide cohort of patients with type 2 diabetes and AF, SGLT2 inhibitor was associated with a lower risk of mortality compared to DPP4 inhibitor, which may suggest that SGLT2 inhibitors may be considered as the first-line antidiabetic medication in patients with type 2 diabetes and AF.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a research grant from the Inha University.(Grant Number: Inha 70431) to S-H Shin.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study complied with the Declaration of Helsinki and was approved by the Institutional Review Board (IRB) of Inha University Hospital (2021-11-022), and informed consent was waived by the IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data supporting the findings of this study are accessible from the Korea National Health Insurance Service, but availability is restricted as these data were utilized under license for the current study and are not publicly accessible. However, the data can be obtained from the Korea National Health Insurance Service upon reasonable request and following the appropriate review process.
